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Objective: Recent evidence suggests an important role for angiotensin-converting 46 
enzyme 2 (ACE2) in limiting abdominal aortic aneurysm (AAA). This study examined 47 
the effect of ACE2 deficiency on AAA development and the efficacy of resveratrol to 48 
up-regulate ACE2 in experimental AAA. 49 
Approach and Results: Ace2 deletion in apolipoprotein-deficient mice (ApoE-/-Ace2-/y) 50 
resulted in increased aortic diameter and spontaneous aneurysm of the suprarenal 51 
aorta (SRA) associated with increased expression of inflammation and proteolytic 52 
enzyme markers. In humans, serum ACE2 activity was negatively associated with AAA 53 
diagnosis. ACE2 expression was lower in infrarenal biopsies of AAA patients than 54 
organ donors. AAA was more severe in ApoE-/-Ace2-/y mice compared to controls in 55 
two experimental models. Resveratrol (0.05 g/100 g chow) inhibited growth of pre-56 
established AAAs in ApoE-/- mice fed high-fat chow and infused with angiotensin II 57 
(AngII) continuously over 56 days. Reduced SRA dilatation in mice receiving 58 
resveratrol was associated with elevated serum ACE2, and increased SRA tissue 59 
levels of ACE2 and sirtuin (Sirt)1 activity.  In addition, the relative phosphorylation of 60 
Akt and extracellular signal-regulated kinase 1/2 within SRA tissue, and gene 61 
expression for nuclear factor of kappa light polypeptide gene enhancer in B cells 1, 62 
angiotensin type-1 receptor, and metallopeptidase 2 and 9 were significantly reduced. 63 
Up-regulation of ACE2 in human aortic smooth muscle cells by resveratrol in vitro was 64 
Sirt1-dependent. 65 
Conclusion: This study provides experimental evidence of an important role for ACE2 66 
in limiting AAA development and growth. Resveratrol upregulated ACE2 and inhibited 67 






AAA abdominal aortic aneurysm 
ACE2 
angiotensin-converting enzyme 2 (gene = ACE2 (human); Ace2 
(mouse)) 
Agtr1 
angiotensin type-1 receptor (gene = AGTR1 (human); Agtr1 
(mouse) 
AngII angiotensin II 
AoSMC human aortic smooth muscle cell  
ApoE-/- apolipoprotein E-deficient mouse 
ApoE-/-Ace2-/y whole-body Ace2-deficient ApoE-/- mouse 
IRA infrarenal aorta 
RSV resveratrol 
Sirt1 sirtuin 1 (gene = SIRT1 (human); Sirt1 (mouse)) 







Abdominal aortic aneurysm (AAA) is an important cause of sudden death due 76 
to aortic rupture and responsible for ~200,000 deaths worldwide each year [1]. Most 77 
AAAs are identified at an early stage when a medical therapy could be instigated to 78 
limit AAA progression. There is great interest in identifying targets for the development 79 
of drug therapy that can effectively limit AAA growth and aortic rupture as no proven 80 
medical treatment is currently available [2,3,4].  81 
Chronic aortic inflammation is thought to play a significant role in AAA 82 
pathogenesis through multiple mechanisms including the release of proteolytic 83 
enzymes from infiltrating leukocytes, and the generation of reactive oxygen species 84 
(ROS) that induce an inflammatory phenotype in vascular smooth muscle cells [5]. The 85 
renin-angiotensin-system (RAS) has long been implicated in human AAA pathogenesis 86 
[4,5]. Angiotensin II (AngII), the primary effector of the RAS, stimulates pro-87 
inflammatory activity in the vascular wall [6]. Historically, angiotensin-converting 88 
enzyme (ACE) and the angiotensin type-1 receptor have been the focus for clinical 89 
interventions targeting the RAS, however, recent studies have demonstrated the 90 
importance of angiotensin-converting enzyme 2 (ACE2) in maintaining the balance of 91 
the RAS [7]. The action of ACE2 to metabolise AngII to vascular-protective peptides 92 
such as angiotensin-1-7 (Ang(1-7)) has identified ACE2 as an important negative 93 
regulator of the RAS [8,9].  94 
Reduced ACE2 expression has been associated with cardiovascular disease in 95 
humans and experimental models [7,10] and therapeutic strategies for augmenting 96 
ACE2 expression and activity are thus being developed [11-15]. Previous studies have 97 
reported that the 3,5,4´-trihydroxy-trans-stilbene resveratrol inhibits experimental 98 
aortic aneurysm and dissection development [16-18]. Resveratrol is reported to up-99 
regulate adipose expression of Ace2 in hyperlipidemic mice [19]. Many of the beneficial 100 
cardiovascular properties attributed to resveratrol are believed to be mediated either 101 
directly or indirectly through activation of the nicotinamide adenine dinucleotide 102 
(NAD+)-dependent deacetylase sirtuin-1 (Sirt1) [20-22]. Moreover, it has recently been 103 
reported that increased ACE2 expression under conditions of cell stress in vitro is 104 
controlled by Sirt1 [23]. Sirt1 exerts protective effects on a number of cellular processes 105 
such as gene regulation, the stress response, apoptosis, inflammation and 106 
senescence [24], which are processes implicated in AAA [5,25,26].  107 
The present study investigated the regulatory role of ACE2 in AAA by assessing 108 
its genetic deletion, firstly, in otherwise unmanipulated apolipoprotein E-deficient 109 
(ApoE-/-) mice, and then in two mouse models of AAA. ACE2 expression was examined 110 
in human serum and aortic tissue samples from AAA patients and controls. Finally, the 111 
efficacy of resveratrol in upregulating ACE2 and limiting AAA growth was investigated 112 
in a mouse model of established AAA and within in vitro studies using human aortic 113 
smooth muscle cells (AoSMC). 114 
 115 
 116 
Material and Methods 117 
 118 










Ace2-deficient ApoE-/- mice were predisposed to AAA development and aortic 126 
rupture  127 
We examined the suprarenal aorta (SRA) and serum of otherwise 128 
unmanipulated ApoE-/- mice deficient in Ace2 (ApoE-/-Ace2-/y) and age and sex-129 
matched ApoE-/- controls. Median maximum diameter of the SRA in ApoE-/-Ace2-/y mice 130 
was significantly larger than that in control mice (Figure 1A). Intriguingly, two of the 131 
Ace2-deficient animals (but none of the controls) exhibited unexpected marked 132 
dilatation of the SRA (Figure 1B). Aortic tissue levels of AngII were greater in ApoE-/-133 
Ace2-/y mice compared to ApoE-/- controls (225 pg/mg protein vs 102 pg/mg, 134 
respectively; n=6, P<0.001). ApoE-/-Ace2-/y mice exhibited markedly upregulated aortic 135 
gene expression for the pro-inflammatory markers interleukin-6, tumour necrosis 136 
factor-α, monocyte chemotactic protein-1, vascular cell adhesion molecule-1, and 137 
Mac-1/CD11b (Supplementary Figure I). Aortic gene expression for the extracellular 138 
matrix proteins collagen I and III, elastin, fibronectin, connective tissue growth factor 139 
(CTGF) and transforming growth factor beta (TGFβ) was similar in ApoE-/-Ace2-/y and 140 
ApoE-/- mice (Supplementary Table I). Aortic gene expression for osteopontin, 141 
osteoprotegerin, matrix metallopeptidase (Mmp)2 and Mmp9 was significantly greater 142 
in ApoE-/-Ace2-/y than ApoE-/- mice (Supplementary Figure I). Lysyl oxidase activity 143 
within aortas of ApoE-/-Ace2-/y mice was down-regulated compared to ApoE-/- controls 144 
(7.1  0.5 relative fluorescence units (RFU)/ug protein vs 12.8  2.8 RFU/ug protein, 145 
respectively; n=8, P=0.025). Serum concentration of AngII was significantly higher in 146 
ApoE-/-Ace2-/y mice compared to ApoE-/- controls (26831 pg/ml vs 13521 pg/ml, 147 
respectively; n=6, P<0.001), while serum total cholesterol (10.30.6 mM vs 10.10.5 148 
mM) and triglyceride (1.10.1 mM vs 1.10.2 mM) concentrations were comparable. 149 
Systolic blood pressure was significantly higher in ApoE-/-Ace2-/y mice compared to 150 
controls (1102 mmHg vs 982 mmHg, respectively; n=8, P<0.001).  151 
The effect of Ace2 deficiency was examined in two models of experimental AAA. 152 
Remarkably, subcutaneous infusion of AngII (1µg/kg/min) resulted in an 83% rupture 153 
rate (10 out of 12 mice) in ApoE-/-Ace2-/y mice within 7 days of pump insertion, 154 
compared to only 15% (2 of the 13) in ApoE-/- controls over the 28-day AngII infusion 155 
period (Figure 1C & 1D; Supplementary Figure II). Ace2 deficiency resulted in more 156 
severe aortic dilatation within the calcium chloride (CaCl2) model. After CaCl2 157 
application, a time-dependent increase in infrarenal aortic (IRA) diameter was 158 
observed by ultrasound in both ApoE-/- (P<0.001, ANOVA) and ApoE-/-Ace2-/y 159 
(P<0.001, ANOVA) mice (Figure 1E). The rate of IRA expansion was markedly greater 160 
in ApoE-/-Ace2-/y than control mice (P=0.034, linear mixed-effects (LME); Figure 1E). 161 
There were no aortic ruptures in either group of mice within the CaCl2 model. At the 162 
end of the study the aortas were harvested from all mice and used to perform 163 
morphometric analyses. A markedly greater percent-increase in IRA diameter (relative 164 
to corresponding sham controls) was demonstrated in ApoE-/-Ace2-/y mice compared 165 
to ApoE-/- controls (Figure 1F; Supplementary Figure III). 166 
 167 
Serum ACE2 activity and aortic expression of ACE2 were reduced in AAA 168 
patients  169 
ACE2 activity was measured in serum samples obtained from 548 participants 170 
of the Health In Men Study (HIMS), comprising 205 men who had an AAA and 343 171 
who did not. Participant demographic characteristics are presented in Supplementary 172 




using binary logistic regression including analyses which adjusted for established AAA 174 
risk factors (Supplementary Table III). ACE2 activity had a significant inverse 175 
association with AAA diagnosis after adjusting for AAA risk factors and potential 176 
confounders (P=0.032; Supplementary Table III). A similar trend was observed in the 177 
unadjusted analysis although the association was not statistically significant (P=0.087).  178 
Expression of ACE and ACE2, and the level of CpG island methylation in the 179 
promoter region of ACE2 (Supplementary Figure IV) were assessed in infrarenal aortic 180 
biopsies collected from patients undergoing open surgery for AAA repair and from 181 
heart-beating brain dead organ donors (controls). Demographic characteristics of the 182 
participants are presented in Supplementary Table IV. Expression of ACE was similar 183 
in AAA and control biopsies (Supplementary Figure V), however ACE2 was down-184 
regulated 8-fold in AAA biopsies compared to controls (P=0.024; Supplementary 185 
Figure V). Hyper-methylation of 12 CpG sites was found in all AAA samples and the 186 
mean percentage CpG island methylation was higher in AAA than control aortic 187 
biopsies (P=0.032; Supplementary Figure VI). 188 
 189 
Growth of pre-induced AAAs was inhibited with dietary resveratrol 190 
supplementation in a mouse model 191 
  Two consecutive 28-day subcutaneous pumps were implanted (day 0 and day 192 
29) in a cohort of high-fat chow (HFC)-fed ApoE-/- mice to supply continuous AngII (1.0 193 
μg/kg/min) over an eight-week experimental period (Supplementary Figure VII). After 194 
an initial 14-day AAA establishment period, surviving mice were allocated to receive 195 
either HFC (control; n=15) or HFC + 0.05 g resveratrol/100 g HFC (intervention; n=15) 196 
diets for the remaining six weeks.   197 
Continuous AngII infusion during the intervention period resulted in a mortality 198 
rate due to aortic rupture of 27% (4 out of 15) in the control (HFC) group versus 7% (1 199 
out of 15) in the intervention (HFC + resveratrol) group (Supplementary Figure VIII). 200 
The reduced rupture rate in mice receiving resveratrol was not statistically significant 201 
(P=0.130, Log-rank test; Supplementary Figure VIII). Body-weight of surviving mice 202 
fed either HFC (P<0.001, ANOVA) or resveratrol-supplemented HFC (P<0.001, 203 
ANOVA) diets increased over the six-week intervention period (Figure 2A). However, 204 
the rate of increase in bodyweight was markedly reduced in mice receiving resveratrol 205 
(P<0.001, LME; Figure 2A). The average amount of food consumed over the 206 
experimental period was comparable between the groups (Supplementary Figure IX).  207 
A time-dependent increase in maximum SRA diameter in response to AngII was 208 
observed by ultrasound in control mice over the six-week period (P<0.001, ANOVA; 209 
Figure 2B). In contrast, the maximum SRA diameter in mice administered HFC diet 210 
supplemented with resveratrol did not change significantly (P=0.318, ANOVA; Figure 211 
2B). Control mice exhibited a substantially greater rate of SRA expansion over the 212 
intervention period compared to mice receiving resveratrol (P=0.034, LME; Figure 2B). 213 
Mice receiving resveratrol that reached the end of the experimental period had 214 
significantly smaller maximum SRA diameter than controls when measured by 215 
morphometry (P<0.001; Figure 2C; Supplementary Figure X). 216 
Serum concentration of ACE2 was determined in all mice at baseline, at the 217 
time of allocation to the interventional and control groups (day 14), and at the 218 
completion of the intervention period. A decrease in serum ACE2 concentration over 219 
time was demonstrated in control mice in response to AngII infusion and HFC diet 220 
(P=0.026, ANOVA; Figure 2D). At the end of the study (day 56), the median serum 221 
concentration of ACE2 in these mice was significantly lower than at baseline (P=0.015; 222 




serum ACE2 concentration (P=0.075 compared to baseline, ANOVA; Figure 2D), and 224 
median concentration of serum ACE2 in mice receiving resveratrol was above baseline 225 
and 4-fold higher than in control mice at the end of the study (P=0.005; Figure 2D).  226 
Ace2 gene expression and protein concentration within the SRA was greater in 227 
mice receiving resveratrol than controls (Table 1; Figure 2E). Sirt1 expression and Sirt1 228 
deacetylase activity within the SRA was markedly greater in mice receiving resveratrol 229 
compared to controls (Table 1; Figure 2F). Protein concentration of total protein kinase 230 
B (Akt1) and extracellular signal-regulated kinase (ERK)1/2 kinases within the SRA 231 
tissue of mice receiving resveratrol were similar to concentrations in control mice 232 
(Supplementary Figure XI). The ratio of phosphorylated-to-total kinase (activity) for 233 
both Akt1 and ERK1/2 within SRA tissue from mice receiving resveratrol was 234 
significantly lower than that within SRA tissue from mice on the control diet (Figure 3).  235 
Gene expression for the inflammatory marker nuclear factor of kappa light polypeptide 236 
gene enhancer in B cells 1 (Nfkb1) and proteolytic enzymes Mmp2 and Mmp9 within 237 
the SRA of mice receiving resveratrol was down-regulated 4.5-, 3-, and 2-fold, 238 
respectively, compared to controls, while gene expression for the angiotensin II type-239 
1 receptor (Agtr1) was 2-fold lower in mice receiving resveratrol compared to controls 240 
(Table 1).  241 
 242 
Normalisation of ACE2 in inflammation-activated human AoSMC via resveratrol-243 
mediated Sirt1 activation  244 
The effect of resveratrol (5 M) on resting human AoSMC, and inflammation-245 
activated AoSMC was examined in vitro. The expression of NFKB1, AGTR1, ACE2, 246 
and SIRT1 genes in resting AoSMC is shown in Table 2. While no significant change 247 
in basal expression of NFKB1 was seen, incubation of cells with resveratrol over 24 248 
hours resulted in a significant decrease in AGTR1 and increases in ACE2 and SIRT1 249 
expression (Table 2).   250 
Cell stress was modelled in AoSMC via exposure to activated monocyte-derived 251 
pro-inflammatory media over five days. Control cells incubated in pro-inflammatory 252 
media alone exhibited marked increases in the expression of NFKB1 and AGTR1, with 253 
significant down-regulation of ACE2 and SIRT1 (Figure 4A-D). The reduction in ACE2 254 
and SIRT1 gene expression correlated with significant reduction in cellular protein and 255 
cellular activity of ACE2 and Sirt1, respectively (Figure 4E&F). Supplementation of the 256 
pro-inflammatory media with 5 M resveratrol during the final 24 hours of the five-day 257 
incubation resulted in changes in expression for all four genes to within baseline 258 
expression ranges (Figure 4A-D). Notably, cellular ACE2 protein and Sirt1 activity were 259 
upregulated and measured at levels significantly higher than baseline (Figure 4E&F).  260 
 The positive effect of resveratrol on gene and protein expression of ACE2 was 261 
ablated upon targeted knock-down of Sirt1 (Figure 5). Gene silencing of SIRT1 in 262 
activated AoSMC performed using small interfering (si) RNA added after 36 hours 263 
incubation in pro-inflammatory media resulted in 2-fold down-regulation in SIRT1 264 
expression (P=0.002; Figure 5A). Supplementation with 5 M resveratrol 24 hours 265 
following SIRT1 silencing failed to correct down-regulated ACE2 expression or cellular 266 












The main finding of this study was that dietary resveratrol supplementation 276 
significantly inhibited progression of AAA in a mouse model. The effect of resveratrol 277 
was associated with up-regulation of ACE2 expression and Sirt1 activity within the 278 
aorta. A link between resveratrol-mediated up-regulation of ACE2 and increased Sirt1 279 
activity was demonstrated in human AoSMC in vitro. 280 
Preclinical and clinical studies have demonstrated that ACE2 deficiency 281 
promotes susceptibility to metabolic and cardiovascular disease [7], however the 282 
importance of ACE2 in AAA has only recently received attention [13,15,27]. Thatcher 283 
et al [13] first reported that Ace2 deficiency in low-density lipoprotein receptor-deficient 284 
mice promoted dilatation of the SRA in response AngII infusion. The current study 285 
supports and extends these finding by reporting increased propensity to AAA 286 
development by ApoE-/-Ace2-/y mice when AAA is induced by either AngII or CaCl2. 287 
Notable was the presence of larger SRA diameter and spontaneous aneurysm in 288 
otherwise unmanipulated ApoE-/-Ace2-/y mice. We and others have reported that Ace2 289 
deficiency predisposes to vascular inflammation in the ApoE-/- mouse [27,28] and 290 
results in increased circulating and tissue levels of AngII [28,29]. Higher concentration 291 
of AngII and increased markers of extracellular matrix inflammation and degeneration 292 
within aortic tissue of ApoE-/-Ace2-/y mice was confirmed in the current study. While 293 
there appeared to be no change in collagen synthesis or in the expression of pro-294 
fibrotic mediators like TGFβ and CTGF, proteolytic enzymes MMP2 and MMP9 were 295 
up-regulated and LOX activity decreased in ApoE-/-Ace2-/y mice. LOX is an 296 
extracellular copper enzyme that initiates crosslinking of collagen and elastin to provide 297 
vascular tensile strength and elasticity, and its deficiency leads to aneurysm formation 298 
and premature death in mice [30,31]. Aortic expression of osteoprotegerin, a protein 299 
that we and others have shown to promote AAA through stimulating protease release 300 
from monocytes and vascular smooth muscle cells [32,33], was increased also in 301 
ApoE-/-Ace2-/y mice compared to ApoE-/- controls. It is highly likely that these pre-302 
existing differences in expression for markers of inflammation and extracellular matrix 303 
turnover, AngII concentration and blood pressure, accounted for the increased SRA 304 
dilatation in ApoE-/-Ace2-/y mice, and predisposed these mice to more severe AngII or 305 
CaCl2-induced aortic aneurysms compared to controls.   306 
Previous investigation of ACE2 in human AAA patients has been limited. 307 
Previous studies that measured plasma or serum ACE2 indicate that circulating ACE2 308 
activity is low in healthy subjects, comparably increased in subjects with cardiovascular 309 
risk factors, and correlated with cardiovascular disease development [34,35]. Here, we 310 
measured serum ACE2 activity in men that did and did not have ultrasound 311 
screeningdetected AAAs and found relative lower levels in men with an AAA after 312 
adjusting for other risk factors. This appears in contrast with existing published data on 313 
circulating ACE2 and cardiovascular disease. Importantly, ACE2 undergoes cleavage 314 
(‘shedding’) to release the catalytically active ectodomain into the extracellular milieu 315 
and circulation [36], however whether the degree of ACE2 activity within the circulation 316 
correlates with tissue ACE2 synthesis and/or ACE2 shedding from tissue remains 317 
uncertain and requires further investigation. We also found the hyper-methylation of 318 
the ACE2 promoter and down-regulation of ACE2 expression in human AAA biopsies 319 
compared to samples from donor controls. Overall these findings suggest down-320 
regulation of ACE2 in AAA patients. Interestingly, low serum ACE2 was recently 321 
reported as an independent risk factor and potential prognostic for in-hospital mortality 322 




The ACE2/Ang(1-7)/mas receptor axis has emerged within the RAS as a 324 
counterbalance to the classical ACE/AngII/AT1R pathway [8,9], and, subsequently, 325 
ACE2 as a potential therapeutic target for the treatment of cardiovascular diseases 326 
[7,38]. Pre-clinically, therapeutic strategies for ACE2 involve augmenting its activity or 327 
expression. To this end, adenovirus-mediated Ace2 gene transfer [15] and ACE2 328 
activation (diminazene aceturate) [13] have been utilised in mouse models of AAA with 329 
promising outcomes. The current study adopted an alternative approach. The natural 330 
dietary 3,5,4´-trihydroxy-trans-stilbene resveratrol has been reported to inhibit AAA 331 
development in several rodent models [16-18], and in an unrelated study, increase fat 332 
tissue Ace2 expression in mice [19]. We investigated the efficacy of resveratrol to 333 
positively regulate aortic Ace2 expression, and limit growth of established AAA in a 334 
mouse model.  335 
Resveratrol administration increased SRA and serum levels of ACE2. The up-336 
regulation of ACE2 in the SRA of mice receiving resveratrol was associated with 337 
concomitant increase in mRNA and activity for Sirt1. Sirt1 is a NAD+-dependent protein 338 
deacetylase highly expressed in the vasculature [39]. An increasing number of 339 
vascular-protective actions for Sirt1, including modulation of stress-induced vascular 340 
remodelling, are being recognised [40,41]. Very recent studies suggest that reduced 341 
Sirt1 production and activity in vascular smooth muscle links vascular senescence and 342 
inflammation to AAA [42]. Sirt1 is a putative target for resveratrol with direct and indirect 343 
mechanisms described for resveratrol activation of Sirt1 [20-22]. Up-regulation of 344 
ACE2 expression by Sirt1 under conditions of energy stress has recently been reported 345 
[23] and is of particular relevance to the current study. We demonstrated in an in vitro 346 
model of inflammation the down-regulation of both ACE2 and Sirt1 in human AoSMC. 347 
More important was that rescue and up-regulation of ACE2 in these cells by resveratrol 348 
was abolished upon pre-incubation of AoSMC with Sirt1-targeted siRNA, thus 349 
establishing a potential dependant link between resveratrol, Sirt1 activation, and 350 
positive regulation of vascular ACE2.  351 
The relative levels of phosphorylated Akt and ERK1/2 within the SRA of ApoE-352 
/- mice have been previously reported to be increased following AngII-infusion [43]. The 353 
Akt and ERK1/2 pathways have been implicated in  the activation of extracellular 354 
remodelling enzymes and inflammation in AAA [44,45]. Notably, ACE2 deficiency has 355 
been reported to promote AngII-mediated aortic inflammation and oxidative stress 356 
associated with the activation of Akt/ERK/eNOS signaling [46]. Resveratrol has been 357 
reported to inhibit ROS overproduction in vascular smooth muscle through suppression 358 
of Akt and p38 MAPK/JNK/ERK phosphorylation [47]. In the current study, we found 359 
marked reduction in the relative levels of phosphorylated Akt and ERK1/2 within SRA 360 
samples of mice receiving resveratrol. This finding suggests that resveratrol 361 
administration led to down-regulation of both the Akt and ERK1/2 signaling pathways. 362 
Aortic expression of Nfkb1, Mmp2, Mmp9, and Agtr1, were also downregulated in mice 363 
receiving resveratrol suggesting that the abovementioned effect of resveratrol resulted 364 
in less aortic inflammation and expression of matrix degrading enzymes. 365 
A number of study limitations are acknowledged. First, sample numbers for the 366 
human infrarenal aortic tissue study were relatively small. As most AAAs are now 367 
managed by endovascular repair, AAA wall biopsies are increasingly difficult to obtain. 368 
Similarly, ethical and practical considerations prevent the collection of aortic biopsies 369 
from large numbers of control donors; however, sample sizes were similar to other 370 
published studies [25,48,49]. Second, the organ donor controls were younger than the 371 
patients with AAA, and the possibility that the age discrepancy may have contributed 372 




for the organ donor controls and variation in cardiovascular risk factors between groups 374 
could not be adjusted for. However, organ donors are often the only viable source of 375 
healthy aortic biopsies. Previous studies have utilized macroscopically healthy tissues 376 
proximal to the AAA sac as matched control tissues [50,51]; but these were not 377 
available for the current study. Third, we did not conclusively demonstrate that the 378 
benefits of resveratrol to limit AAA growth resulted from ACE2 upregulation. Ideally a 379 
study of the effect of resveratrol in ApoE-/-Ace2-/y mice and ApoE-/- controls would have 380 
been performed but was not feasible due to the substantial aortic rupture rate in ApoE-381 
/-Ace2-/y mice in response to AngII. Finally, in vitro studies were conducted only in 382 
AoSMC. We acknowledge that resveratrol has been shown to improve endothelial 383 
function and increased expression of ACE2 has been reported to promote positive 384 
endothelial responses to inflammation [52,53]. It is therefore possible that the 385 
beneficial effects of resveratrol may have been due to effects on endothelial or even 386 
inflammatory cells. However the current study focused on progression of established 387 
AAA. A recognised feature of AAA progression in humans is phenotypic change, 388 
accelerated replicative senescence, apoptosis, and subsequent depletion of medial 389 
AoSMC [26,54]. This and recent evidence that ACE2 deficiency in AoSMC markedly 390 
increases ROS and apoptosis in response to AngII [27] formed the basis for the 391 
rationale to focus in vitro studies on AoSMC.  392 
In summary, the current study provides further experimental evidence of an 393 
important role for ACE2 in vascular homeostasis and as a modulator of AAA severity. 394 
Dietary administration of resveratrol upregulated ACE2 and inhibited AAA progression 395 
in a mouse model. The up-regulation of aortic ACE2 was paralleled by increased 396 
expression and activity of Sirt1, and down-regulation of key signaling pathways and 397 
markers of inflammation. Resveratrol rescued AoSMC expression and production of 398 
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 ACE2 deficiency promoted experimental AAA development and rupture  
 ACE2 expression was down-regulated in human AAA patients 
 Resveratrol inhibited progression of experimental AAA associated with up-
regulation of aortic ACE2  







































Figure 1: Predisposition of ApoE-/-Ace2-/y mice to aortic dilatation. Larger 
maximum SRA diameter (A) and SRA aneurysms (arrow; B) in otherwise 
unmanipulated ApoE-/-Ace2-/y mice compared to ApoE-/- control mice. Data expressed 
as median and interquartile range with maximum and minimum data points (whiskers) 
for maximum SRA diameter (mm; A). C. Kaplan-Meier curves illustrating survival data 
for AngII-infused ApoE-/-Ace2-/y (open circle) and ApoE-/- mice (closed circle); P-value 
calculated using Log-rank (Mantel-Cox) test.  D. Incidence of aortic rupture (black) 
within total number of mice per group (gray); *P=0.001 compared with control by Fisher 
exact test. E. Ultrasound measurement of infra-renal (IRA) dilatation induced by CaCl2 
over 28 days in ApoE-/-Ace2-/y (white bar) compared to ApoE-/- control mice (grey bar). 
Data expressed as median and interquartile range with maximum and minimum data 
points (whiskers) for maximum diameter (mm); P-value calculated for difference 
between groups by mixed-effects linear regression. F. Increase in IRA diameter 
induced by CaCl2 in ApoE-/-Ace2-/y mice compared to ApoE-/- controls. Data expressed 
as median and interquartile range with maximum and minimum data points (whiskers) 







Figure 2: Effect of resveratrol in an AngII-infused, high fat-fed, ApoE-/- model of 
established AAA. Bodyweight (A) and ultrasound measurement of the SRA (B) in 
ApoE-/- mice receiving high-fat chow (HFC; grey) and HFC + 0.05 g resveratrol/100 g 
HFC (white). Data expressed as median and interquartile range with maximum and 
minimum data points (whiskers) for bodyweight (g; A) and maximum SRA diameter 
(mm; B); P-values calculated for difference between groups by mixed-effects linear 
regression. C. Maximum SRA diameter at the end of the study in ApoE-/- mice receiving 
control diet (HFC) and resveratrol-supplemented diet (HFC + 0.05 g resveratrol/100 g 
HFC). Data expressed as median and interquartile range with maximum and minimum 
data points (whiskers) for diameter (mm). D. Serum ACE2 concentration at baseline, 
14 days, and 56 days during an AngII infusion in ApoE-/- mice receiving HFC, and at 
day 56 in ApoE-/- mice receiving HFC supplemented with resveratrol (RSV). Data 
expressed as median and interquartile range with maximum and minimum data points 
(whiskers) for concentration (pg/ml); *P=0.005 compared with controls at day 56 by 
Mann-Whitney U test. Sirtuin 1 (SIRT1) activity (E) and ACE2 (F) measured at the end 
of the study within SRA tissue of ApoE-/- mice receiving HFC versus HFC 
supplemented with resveratrol (RSV). Data expressed as median and interquartile 
range with maximum and minimum data points (whiskers) for deacetylase activity 





























Figure 3: Resveratrol down-regulated aortic Akt and ERK1/2 phosphorylation in 
AngII-infused, high-fat fed ApoE-/- mice. Ratio of phosphorylated-to-total Akt1 and 
ERK1/2 in SRA tissue of mice fed control diet (grey) or resveratrol-supplemented diet 
(white). Data expressed as median and interquartile range with maximum and 















































Figure 4: Effect of resveratrol (RSV) on inflammation-activated human AoSMC. 
Gene expression for NFκB (A), AGTR1 (B), ACE2 (C), and SIRT1 (D), cellular ACE2 
(E) and cellular SIRT1 activity (F) in a model of AoSMC inflammation induced by 
incubation of cultures in 10% v/v pro-inflammatory media (PIM) generated from 
lipopolysaccharide-stimulated monocytic THP-1 cells, and in the presence and 
absence of resveratrol (RSV; 5 μM). Data expressed as median and interquartile range 
with maximum and minimum data points (whiskers) for expression relative to GAPDH 






Figure 5: Sirt1-dependent up-regulation of 
ACE2 by resveratrol in inflammation-
activated human AoSMC. A. siRNA-targeted 
silencing of SIRT1 gene in a model of AoSMC 
inflammation induced by incubation of cultures 
in 10% v/v pro-inflammatory media (PIM). 
Data expressed as median and interquartile 
range with maximum and minimum data 
points (whiskers) for expression relative to 
GAPDH. Gene (B) and cellular (C) expression 
of ACE2 in inflamed AoSMC (PIM) in the 
presence and absence of resveratrol (RSV) 
and siRNA for SIRT1. Data expressed as 
median and interquartile range with maximum 
and minimum data points (whiskers) for 
expression relative to GAPDH (B) or pg/105 





















Table 1:  Effect of resveratrol (RSV) on gene expression in  pre-established, 





AngII+HFC+RSV Expression P 
 (n=11) (n=14)   
Ace2 0.64 (0.49-0.92) 1.72 (1.12-2.49)  0.008 
Sirt1 1.81 (1.25-2.18) 2.86 (2.30-3.52)  0.004 
Nfkb1 3.26 (1.89-3.85) 0.72 (0.25-1.77)  <0.001 
Mmp9 1.99 (0.91-17.63) 0.74 (0.46-2.15)  0.015 
Mmp2 3.59 (2.21-7.98) 1.72 (0.40-2.76)  0.067 
Agtr1 2.67 (1.32-3.85) 1.17 (0.82-1.93)  0.009 
Data expressed as median (interquartile range) mRNA expression relative to 
Gapdh; P, two-sided p-value for comparison by Mann-Whitney U test. Ace2, 
angiotensin-converting enzyme 2; Agtr1, angiotensin II type-1 receptor; Nfkb1, 
nuclear factor of kappa light polypeptide gene enhancer in B cells 1; Mmp, matrix 
metallopeptidase; Sirt1, Sirtuin 1. 
Table 2:  Effect of resveratrol (RSV) over 24 hours on  gene expression for 
NFκB, angiotensin II type 1 receptor (AGTR1), ACE2, and sirtuin 1 (SIRT1) in  
resting human AoSMC  in vitro 
Gene Control RSV Expression P 
 (n=6 repeat cultures) (n=6 repeat cultures)   
NFKB1 1.09 (0.99-1.20) 1.07 (0.94-1.19) NC 0.937 
AGTR1 1.82 (1.75-2.01) 0.94 (0.85-1.03)  0.002 
ACE2 0.59 (0.49-0.62) 0.64 (0.61-0.66)  0.026 
SIRT1 0.76 (0.73-0.91) 0.97 (0.94-1.07)  0.064 
Data expressed as median (interquartile range) mRNA expression relative to 
GAPDH; P, two-sided p-value for comparison between control and intervention by 






Resveratrol inhibits growth of experimental abdominal aortic aneurysm 
associated with upregulation of angiotensin converting enzyme 2  
Moran CS, Biros E, Krishna SM, Wang Y, Tikellis C, Moxon JV, Cooper ME, Norman 
PE, Burrell LM, Thomas MC, Golledge J 
 
 




























Figure I: Aortic expression of selected markers of vascular inflammation. Increased 
expression of genes associated with inflammation and proteolytic activity measured in the 
aortas of otherwise unmanipulated ApoE-/-Ace2-/y mice. Data expressed as mean and SD 
expression relative to ApoE-/- controls (grey);  * P<0.05, compared by unpaired t-test (n=8 per 
group). IL, interleukin; MCP-1, monocyte chemoattractant protein-1; MMP, matrix 
metalloproteinase; OPG, osteoprotegerin; OPN, osteopontin; TNF, tumor necrosis factor; 

















Figure II: Effect of Ace2 deficiency on aortic response to AngII. Gross morphology of 
aortas harvested from ApoE-/- (control) and Ace2-deficient (ApoE-/-Ace2-/y) mice infused with 






































Figure III: Effect of ACE2 deficiency 
on aortic response to calcium 
chloride (CaCl2). Gross morphology (A) 
and maximum diameter (B) of infrarenal 
aortas (IRA) harvested from ApoE-/- and 
ApoE-/-Ace2-/y mice after 28 days, in 
which aneurysm was induced by 
perivascular application of 0.5 M calcium 
chloride (CaCl2). Sham vessels were 
applied with sodium chloride. Data 
expressed as median and interquartile 
range with maximum and minimum data 










Figure IV: A schematic representation of the promoter region of ACE-2 gene. The red line 
denotes the input ACE-2 sequence along with 1000 base pairs (bp) upstream sequence from 
Transcription start site (TSS) submitted to the Methprimer software. The CpG islands are 

























Figure V: Expression of ACE and ACE2 in human AAA. Gene expression for ACE and 
ACE2 in infrarenal aortic biopsies collected from patients undergoing open surgery to repair 
abdominal aortic aneurysm (AAA; white bar) and from non-aneurysmal heart-beating brain 
dead organ donors (Control; grey bar). Data expressed as (log10) median and interquartile 



























Figure VI: ACE2 promotor DNA methylation. Methylation of CpG sites within the ACE2 
promotor region in human infrarenal aortic biopsies collected from patients undergoing open 
surgery to repair abdominal aortic aneurysm (AAA; n=30) and from non-aneurysmal heart-
beating brain dead organ donors (Control; n=30). Data expressed as median and interquartile 






Figure VII: Study design and timeline over 56 days for resveratrol supplementation in 
AngII/ApoE-/- mouse model. Chronic infusion of AngII facilitated by using two 28-day 
subcutaneous ALZET minipumps. HFC, high-fat chow; RSV, resveratrol (HFC supplemented 



































Figure VIII: Model survival. Kaplan-Meier curves of survival free from aneurysm rupture in a 
chronic model of AngII-induced AAA in which ApoE-/- mice were administered HFC diet (white; 
control) or HFC + 0.05 g resveratrol/100 g chow (grey) over 42 days. P-value calculated using 
























Figure IX: Consumption of diet. Average weekly consumption of feed by AngII-infused 
ApoE-/- mice administered HFC diet (grey; control) or HFC + 0.05 g resveratrol/100 g chow 
(white) over 42 days. Data expressed as mean and SD feed consumed (g/mouse/day) and 























Figure X: Effect of resveratrol on aortic response in a chronic model of AAA. Gross 
morphology of aortas harvested from ApoE-/- mice in a chronic model of AngII-induced AAA 
administered either HFC diet (grey; control) or HFC + 0.05 g resveratrol/100 g chow (white) 

























Figure XI: Akt1 and ERK1/2 phosphorylation in the SRA of AngII-infused, high fat-fed, 
ApoE-/- mice. Quantification of total and phosphorylated (Phospho) Akt1 and ERK1/3 in SRA 
tissue of mice receiving control diet (grey) or diet supplemented with resveratrol (white). Data 
expressed as median and interquartile range with maximum and minimum data points 












Table I: Aortic expression of genes associated with matrix synthesis 
Gene n ApoE-/- ApoE-/-Ace2-/y P 
Col1a1 8 1.0 ± 0.2 1.1 ± 0.2 >0.999 
Col3a1 8 1.0 ± 0.1 1.3 ± 0.3 >0.999 
Tgfb1 8 1.1 ± 0.3 1.0 ± 0.2 >0.999 
Ctgf 8 1.0 ± 0.1 1.2 ± 0.1 >0.999 
Fn1 8 1.0 ± 0.1 1.1 ± 0.1 >0.999 
Eln 8 1.0 ± 0.2 0.9 ± 0.3 >0.999 
Data expressed as MeanSEM expression relative to Gapdh;  P, two-sided p-value for 
comparison between control and intervention by Mann-Whitney U test. Col1a1, collagen 
1; Col3a1, collagen III; Tgfb1, TGFβ; Ctgf, connective tissue growth factor; Fn1, 
























Men without AAA 
(n=343) 
Men with AAA 
(n=205) 
P 
Age (years) 72.0 (68.0-75.0) 72.0 (68.0-75.0) 71.0 (68.0-75.0) 0.537 
Infra-renal aortic diameter 
(mm) 
20.2 (19.2-32.2) 19.5 (19.2-20.2) 33.4 (31.6-38.1) <0.001 
BMI (kg/m2) 26.6 (24.4-28.7) 26.4 (24.2-28.5) 27.0 (24.9-29.3) 0.009 





153.0 (142.0-168.5) 0.513 
Diastolic blood pressure 
(mm/Hg) 
90.0 (81.0-97.0) 90.0 (81.0-97.0) 82.0 (90.0-99.0) 0.225 
History of 
Ever smoking 391 (71.4%) 217 174 <0.001 
Diagnosed hypertension 218 (39.8%) [24] 122 (35.6%) [23] 96 (46.8%) [1] 0.043 
Treatment for hypertension 182 (33.2%) [24] 94 (27.4%) 88 (42.9%) 0.001 
Diagnosed diabetes 53 (9.7%) [1] 33 (9.6%) 20 (9.8%) [1] 0.944 
Treatment for diabetes 52 (9.5%) [1] 32 (9.3%) 20 (9.8%) [1] 0.855 
Diagnosed 
hyercholesterolaemia 
214 (39.1%) [24] 126 (36.7%) [23] 88 (42.9%) [1] 0.393 
Treatment for dyslipidaemia 126 (23.0%) [24] 68 (19.8%) [23] 58 (28.3%) [1] 0.061 
Stroke 36 (6.6%) [24] 18 (5.2%) [23] 18 (8.8%) [1] 0.158 
Myocardial infarction 93 (17.0%) [24] 43 (12.5%) [23] 50 (24.4%) [1] 0.001 
     
Serum ACE2 activity 








Continuous data shown as median and inter-quartile range, and are compared between groups using the Mann-Whitney 
U test. Categorical variables shown as count and percent, and are compared using the Chi-squared test. Square 




Table III: Association of serum ACE2 activity with AAA diagnosis by logistic 
regression 
Covariate Odds ratio 95% Confidence interval P 
 
Model 1: Unadjusted analysis 
ACE2 activity 0.849* 0.704-1.024 0.087 
 
Model 2: Adjusted for risk factors for AAA, and differences observed 
between groups on univariate analysis 
ACE2 activity 0.808* 0.665-0.981 0.032 
Age 1.139** 0.906-1.432 0.264 
Ever smoking 3.181 2.009-5.037 <0.001 
Diabetes 0.744 0.401-1.379 0.347 
BMI 1.359*** 1.123-1.645 0.002 
History of 
hypertension 




2.016 1.246-3.262 0.004 
*Odds ratio relates to a 1 std dev increase in serum ACE2 activity (529.5 (arbitrary 
fluorescence units)). ** Odds ratio relates to a 5-year increase in age; *** Odds ratio relates 
to a 1 std deviation increase in BMI (3.3 units); For categorical variables, men who have 




Table IV: Characteristics of subjects for which ACE2 promotor DNA 
methylation was assessed in infrarenal aortic biopsies 
Characteristic AAA No AAA* P 
Number of individuals 30 30 - 
Entry age (years) 70.8±3.6 42.7±13.6 <0.001 
Aortic diameter (mm) 63.8±18.8 - - 
Body mass index (kg/m2) 28.7±4.3 - - 
Male gender 12 (100%) 4 (67%) 0.098 
Smoking history 8 (67%) - - 
Hypertension 7 (58%) - - 
Diabetes mellitus 1 (8%) - - 
Coronary heart disease 4 (33%) - - 
Dyslipidemia 7 (58%) - - 
Nominal variables presented as counts (percentage), and continuous variables presented 
as mean ± standard deviation (SD). Nominal and continuous variables compared between 
subjects using Fisher exact test and Mann Whitney U test, respectively. * Heart-beating 
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Detailed Materials and Methods 
 
Human AAA  
This study was approved by the ethics committees of the Townsville Hospital and Health 
Services, James Cook University, the University of Western Australia and Leiden University 
Medical Center and the protocols conformed to the ethical guidelines of the Declaration of 
Helsinki.  
Serum ACE2 activity: Five hundred and 48 participants of the Health In Men Study (HIMS) 
with available blood samples were included in the current study. The HIMS was a 
community-based screening trial for AAA and the protocols and cohort characteristics have 
been previously detailed [1]. Clinical information collected from each participant included 
age, smoking history, prior diagnosis, or treatment for hypertension, diabetes, 
dyslipidaemia, myocardial infarction or stroke, and blood pressure. Enzymatic activity of 
ACE2 in serum samples was measured by a fluorescence-based assay using the 
commercially available synthetic fluorogenic ACE2 substrate Mca-APK (Dnp) (Enzo, USA). 
A buffer solution containing 50mM MES, 300mM NaCl, 10µM ZnCl2, 1mM N-ethylmaleimide 
(NEM) (Sigma Aldrich) and 0.01% Triton X-100 (Labchem, Australia) was prepared and the 
pH of the buffer adjusted to 6.5. All the reactions were performed in duplicates in black 96 
well plates with a total volume of 100µl. 50mM EDTA (Sigma Aldrich) was added to one of 
the duplicate wells and was constituted a blank. An inhibitor cocktail (Complete EDTA-free 
tablets; Roche, Switzerland) and 2mM phenylmethylsulfonyl fluoride (PMSF; Sigma Aldrich) 
were added to all the wells to prevent the hydrolysis of the ACE2 substrate by the non-
metalloprotease enzymes potentially present in samples. Fluorescence was measured 
using the Enspire Multimode Plate Reader (Perkin Elmer, MA, USA) at 330-nm excitation 
and 400-nm emission wavelength following a 16-hour incubation on a shaker at room 
temperature. ACE2 activity was defined as the difference between the fluorescence 
measured in duplicate wells with and without EDTA addition. 
Aortic ACE2 gene expression and ACE2 DNA methylation: Infrarenal aortic samples 
were collected from patients undergoing open surgery for AAA repair and from heart-beating 
brain dead organ donors (controls). Full thickness AAA biopsies (n=30) from the anterior 
wall of the aneurysm body (site of maximum aortic dilation) and juxtarenal aortic control 
samples (n=30) were snap frozen and stored in -800C for DNA extraction. Aortic samples 
from a subgroup of 12 patients with AAA and six organ donors were stored in RNA later for 
total RNA extraction. Gene expression of ACE2 (QT00034055; Qiagen) was assessed using 
quantitative real-time reverse transcription PCR. The relative expression of ACE2 in each 
sample was calculated by using the concentration-Ct-standard curve method and 
normalized using the average expression of glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH; QT00079247; Qiagen). The ACE2 promoter region includes 12 CpG sites and 
methylation data obtained from the 12 sites were used for analysis. CpG islands in the 
promoter region of the ACE2 gene were identified using the MethPrimer software. Promoter 
specific methylation was assessed analysing PCR fragments by Sequenom MassArray and 
EpiTYPER software as previously reported [2]. The percentage of methylation for the ACE2 
gene promoter was defined as the average of methylation values across the sample and 





Mouse models and in vivo studies 
Approval for the animal studies was obtained from the local ethics committee and 
experimental work performed in accordance with the institutional and ethical guidelines of 
James Cook University, Australia (AEC approvals A2077 & A2358), and conformed to the 
Guide for the Care and Use of Laboratory Animals (National Institutes of Health, USA). Mice 
were housed in an individually-ventilated, temperature and humidity-controlled cage system 
(Aero IVC Green Line; Tecniplast) on a 12-hour light/dark cycle, and maintained on normal 
laboratory chow and water ad libitum until under experimental conditions. 
Mice: Male ACE2-null apolipoprotein E-deficient (ApoE-/-Ace2-/y) mice and age and sex-
matched ApoE-/- mice (both on a C57BL/6 genetic background) were generated as 
previously described [3].  
AAA models: The angiotensin II (AngII) model was implemented as previously described 
[4,5]. Chronic infusion was facilitated using two osmotic micro-pumps (ALZET Model 1004, 
Durect Corporation) containing AngII (#A9525, Sigma-Aldrich) dissolved in sterile water, one 
inserted at day 0 and one at day 28, into the subcutaneous space left of the dorsal midline 
under anaesthesia (4% isoflurane), to administer AngII at a rate of 1.0 μg/kg/min 
continuously over 56 days. Induction of AAA by periaortic application of calcium chloride 
(CaCl2) was performed as previously described [6]. Briefly, CaCl2 solution (0.5 M) was 
applied for 15 minutes to the adventitia of the infra-renal abdominal aorta (IRA) exposed 
under 4% isoflurane anaesthesia. Sham controls underwent a similar procedure except 
0.9% sodium chloride was applied to the IRA adventitia in place of CaCl2.  
Intervention diet: High-fat chow (HFC; modified AIN93G semi-pure rodent diet SF08-043 
(45% calculated energy from ghee, 1.25% cholesterol) supplemented with trans-resveratrol 
(Chem-Supply, Australia; 0.05 g per 100 g HFC) was prepared by a commercial supplier 
(Specialty Feeds, Australia). 
Studies: Four separate studies were performed: 
i) Baseline cardiovascular parameters in ApoE-/-Ace2-/y mice. Protein and molecular 
analyses of serum and suprarenal aorta (SRA), and blood pressure, were compared 
between otherwise unmanipulated 14-week old male ApoE-/- (n=6) and ApoE-/-Ace2-/y mice 
(n=6). 
ii) Effect of ACE2 deficiency on AngII-induced AAA. 14-week old male ApoE-/-Ace2-/y mice 
(n=12) and ApoE-/- controls (n=13) were infused with AngII (1.0 μg/kg/min) over 28 days.  
iii) Effect of ACE2 deficiency on CaCl2-induced AAA. AAAs were induced in 14-week old 
male ApoE-/-Ace2-/y mice (n=10) and ApoE-/- (n=10) controls by perivascular application of 
0.5 M CaCl2 and mice assessed over 28 days.  
iv Effect of resveratrol on ACE2 and growth of pre-established AAAs. 14-week old male 
ApoE-/- mice were chronically infused with AngII (1.0 μg/kg/min) over an eight-week period.  
After an initial 14-day AAA establishment period, mice were allocated to HFC (control; n=15) 
and HFC + 0.05 g resveratrol/100 g chow (intervention; n=15) groups for the remaining six 
weeks. Allocation was based upon ultrasound measurement of SRA diameter such that 
median and interquartile range were similarly matched between the two groups.  
 
Assessment of experimental AAA 
Maximum diameter of the SRA (from the aortic hiatus to the left renal artery) and IRA (from 
left renal artery to the aortic bifurcation) was determined by morphometric analysis ex vivo, 
while in vivo diameter of these arterial segments was monitored by ultrasound as previously 
described [6].  Necropsy was performed within 24 hours of sudden mouse fatality to confirm 
aortic rupture as the cause of death. Phosphate buffered saline-perfused aortas were 
harvested from mice completing the study protocol and were placed on a graduated 
template and digitally photographed (Coolpix 4500, Nikon). Maximum SRA and IRA 




Photoshop CS6 Extended version 13, Adobe Systems Incorporated). Ultrasound 
measurements of the IRA (study iii) were obtained prior to CaCl2 application (day 0) then 
weekly throughout the study (day 7, 14, 21, and 28). Ultrasound measurements of the SRA 
(study iv) were obtained prior to AngII infusion (day 0) and every two week throughout the 
study (day 14, 28, 42 and 56). Scans were performed in sedated mice (4% isoflurane) using 
a MyLabTM 70 VETXV platform (Esaote, Italy) with a 40 mm linear transducer at an 
operating frequency of 10 MHz (LA435; Esaote, Italy) to provide a sagittal image of the SRA. 
Maximum outer wall SRA diameter was measured at peak systole using the calliper 
measurement feature. Good inter-observer reproducibility of morphometric and ultrasound 
analysis has been demonstrated previously in our laboratory [6]. 
 
Blood Pressure  
Blood pressure was measured using a computerized, non-invasive, tail-cuff system (Kent 
Scientific, USA). Animals were habituated to the device before measuring the pressures to 
ensure accurate measurements. Good reproducibility of this technique has been established 
previously (mean of absolute difference for mean blood pressure: 12.3 mmHg, 95% CI: 8.4–
16.1) [7]. 
 
Measurement of angiotensin II 
Serum and aortic concentrations of AngII were measured in ApoE-/- and ApoE-/-Ace2-/y mice 
using a commercially available radioimmunoassay (ProSearch International, Malvern) as 
per the manufacturer’s instructions as previously described [8]. 
 
Serum cholesterol and triglycerides 
Circulating concentrations of cholesterol and triglyceride were determined in serum samples 
from ApoE-/- and ApoE-/-Ace2-/y mice using the automated Abbott Architect ci8200an 
platform (Abbott Laboratories, USA). 
 
Aortic lysyl oxidase activity 
Aortic activity of lysyl oxidase (LOX) was measured in ApoE-/- and ApoE-/-Ace2-/y mice using 
the commercially available Amplite™ Fluorimetric Lysyl Oxidase Assay (AAT Bioquest® 
Inc.) as per the manufacturer’s instructions. 
 
Cell culture 
Healthy human aortic vascular smooth muscle cells (AoSMC; Clonetics® human aortic 
SMC, Lonza) were seeded at 1x105 cells/ml into separate cultures and maintained in 
Dulbecco’s Modified Eagle Medium (DMEM; Sigma-Aldrich) supplemented with 10% fetal 
bovine serum (FBS; Gibco). Cells were growth arrested at ~90% confluency by incubation 
in DMEM + 0.1% FBS overnight (18 hours). Chronic inflammation-induced activation of cells 
was modelled by incubation of cultures in DMEM + 10% FBS comprising 10% v/v 
conditioned media generated from human monocytic THP-1 cells exposed to 10 µg/ml 
endotoxin (Lipopolysaccharide; Sigma-Aldrich) over a period of five days (control cells, n=6 
repeat cultures). Experimental cultures (n=6 repeat cultures) were exposed to the same pro-
inflammatory media but supplemented with resveratrol (5 µM; R5010, Sigma-Aldrich) over 
the final 24-hour period. Gene silencing of Sirt1 was performed using small interfering (si) 
RNA (FlexiTube siRNA, SI00098434, Qiagen) added to culture 48 hours prior to cell harvest. 
Harvested cells were prepared for protein and molecular analysis. 
 
Measurement of ACE2  
A commercially available sandwich high sensitivity ELISA was used to determine the 




Biological Technology) and in serum and the suprarenal aorta (SRA) of experimental mice 
(EK1188, Boster Biological Technology), as per the manufacturer’s instructions. Gene 
expression for ACE2 in mouse SRA was determined by quantitative real-time PCR. 
 
Measurement of Sirt1 activity 
Cellular and aortic Sirt1 deacetylase activity was measured in cultured human AoSMC and 
experimental mice, respectively, using a commercially available activity assay (CS1040, 
Sigma Aldrich) as per the manufacturer’s instructions. The two-step protocol involved first 
the deacetylation by Sirt1 of an acetylated lysine side chain-containing substrate, followed 
by cleavage of the deacetylated substrate by a developing solution and release of a highly 
fluorescent group. The measured fluorescence was directly proportional to the deacetylation 
activity of the enzyme within the sample. 
 
Measurement of Aortic AKT1 and ERK1/2 
Protein from SRA samples harvested at the end of the study was extracted by 
homogenisation in RIPA buffer (Sigma-Alrdrich) and the concentration determined using 
Bradford reagent (Bio-Rad Laboratories) according to the manufacturer's recommendations. 
Measurement of phosphorylated and total AKT1 (AKT 1/2/3 (pS473) + Total AKT1) and 
ERK1/2 (ERK1/2 (pT202/Y204) + Total ERK1/2; Abcam) was performed using a SimpleStep 
ELISA™ (Abcam) as per manufacturer’s instructions.    
 
Quantitative real-time PCR 
QuantiTect® Primer Assays were used to determine gene expression for ACE2 
(QT00034055), Sirt1 (QT00051261), NFKB1 (QT00063791), and AGTR1 (QT00233548) in 
human tissue samples and AoSMC, and ACE2 (QT00111293), Sirt1 (QT01055642), Nfkb 
(QT00154091), Agtr1 (QT00261464), Col1a1 (QT00162204),  Col3a1 (QT01055516), Tgfb1 
(QT00145250), Ctgf (QT00096131), Fn1 (QT00135758), Eln (QT01070482), Il6  
(QT00098875), Tnf (QT00104006), Ccl2 (QT00167832), Vcam1 (QT00128793), Itgam 
(QT00116116), Spp1 (QT00157724), Tnfrsf11b (QT00116116), Mmp2 (QT00116116) and 
Mmp9 (QT00108815) in mouse aortas using quantitative real time (qPCR) as previously 
described [9]. The relative expression of these genes in experimental and control samples 
was calculated by using the concentration-Ct-standard curve method and normalized using 
the average expression of glyceraldehyde-3-phosphate dehydrogenase (human GAPDH, 
QT00079247; mouse Gapdh; QT01658692) for each sample using the Rotor-Gene Q 
operating software version 2.0.24. The QuantiTect SYBR® Green one-step RT-PCR Kit 
(Qiagen) was used according to the manufacturer’s instructions with 40ng of total RNA as 
template. All reactions were independently repeated in duplicate and the mean of the two 
values for each sample was used for analyses.  
Statistical analysis  
Data were analysed using GraphPad Prism (version 6) and TIBCO Spotfire S+ (version 8.2). 
D’Agostino and Pearson’s test was used to test normality of the data, and parametric or non-
parametric tests were applied appropriate to data distribution. Comparison of in vitro end-
point data was performed using Mann-Whitney U test. For animal studies, aortic end-point 
data for maximum diameter and protein or gene expression were compared between control 
and intervention animals by Mann-Whitney U test. Comparison between baseline and end-
point serum or tissue concentrations was performed within each mouse group using paired-




Mann-Whitney U test. Mouse data obtained as a function of time (ultrasound of SRA 
diameter, body-weight) was compared within each group by repeat measures one-way 
ANOVA, and between control and intervention mice by mixed-effects linear regression 
(MLE). Kaplan-Meier survival curves were analysed using log-rank (Mantel-Cox) test. In all 
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